TPST

Rating neutralAI Memo

Tempest Therapeutics

As of 2026-06-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

June 2026 stockholder approval removed a key gating item for warrant-linked share issuance • 2026-06-18

Expected move: -8%

Biggest risk

The bear case is that TPST remains a low-coverage micro-cap biotech with financing dependence, warrant-related dilution overhang, and substantial clinical and regulatory execution still ahead before TPST-2003 optionality can be realized [#SEC-8K-2026-03-30] [#8-K-2026-06-23].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The bull case is that TPST-2003 has unusually strong early efficacy and tolerability signals for a micro-cap platform story, with manufacturing-transfer milestones, a planned U.S. registrational path later in 2026, and a separate partner-funded China BLA path planned for 2027 providing multiple routes to re-rate if execution stays on track [#SEC-8K-2026-05-14] [#SEC-8K-2026-03-30].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-06-25

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway and financing pressure remain the dominant near-term setup
TPST-2003 registrational preparation is the main upside driver into late 2026
Partner-funded China BLA and business-development path are separate long-horizon options

BearKey bullets

Financing remains central because the March 2026 update described only $2 million upfront in the private placement, with additional proceeds dependent on warrant exercise [#SEC-8K-2026-03-30].
Large warrant stack and June 2026 stockholder approvals create ongoing dilution and exercise-overhang risk [#8-K-2026-06-23].
Low coverage and sparse external revision data make post-catalyst price discovery volatile and confidence low.

WatchKey bullets

June 2026 stockholder approval removed a key gating item for warrant-linked share issuance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Bull/Bear spread: +147% / -64%

Vs latest close: Bull +147% · Base -8% · Bear -64%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

This remains a filing-led, low-buzz micro-cap biotech setup. The evidence packet shows no recent trusted-news flow beyond company/SEC materials and no usable social coverage, while the deterministic prior is negative; the June 23, 2026 8-K confirmed stockholder approval for additional warrant-linked share issuance, and the distinct long-horizon upside hooks are TPST-2003 U.S. registrational preparation plus the partner-funded China BLA and BD/licensing path rather than broad sentiment momentum.

As of 2026-06-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway and financing pressure remain the dominant near-term setup
TPST-2003 registrational preparation is the main upside driver into late 2026
Partner-funded China BLA and business-development path are separate long-horizon options

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Price $1 as of 2026-07-10

Nearest Scenario: Base (∆ 8%)

Targets vs latest close: Bull +147% · Base -8% · Bear -64%

Sentiment & Exposure

News Sentiment (30d)

-0.30

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-18
June 2026 stockholder approval removed a key gating item for warrant-linked share issuance
The June 18, 2026 special meeting approved Nasdaq Rule 5635 proposals covering up to 1,851,854 shares tied to March 2026 Series A and B warrants and up to 2,344,828 shares tied to the May 2026 inducement-related common warrants, which reduces a procedural overhang but keeps dilution and financing mechanics front and center [#8-K-2026-06-23].
Prob 85.00% • Move -12.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Runway and financing pressure remain the dominant near-term setup
2026-09-30
Tempest's March 2026 update described an up to $6 million private placement with $2 million upfront and up to $4 million of potential warrant-exercise proceeds, while the broader filing set keeps financing and dilution mechanics central to the near-term stock setup [#SEC-8K-2026-03-30].
Prob 80% • Move -18% • Priced-in 70%

Long-term Catalysts

Months to a year

TPST-2003 registrational preparation is the main upside driver into late 2026
2026-12-31
Tempest said interim TPST-2003 data across REDEEM-1 and POEMS-1 showed a 100% complete response rate among 15 CAR-T-naive efficacy-evaluable patients, no Grade 3 or higher CRS or ICANS in REDEEM-1, and AGCTC was selected as lead manufacturing partner with lentiviral vector delivery completed to support a planned U.S. registrational study later in 2026 [#SEC-8K-2026-05-14].
Prob 50% • Move 70% • Priced-in 30%
Partner-funded China BLA and business-development path are separate long-horizon options
2027-12-31
The March 2026 business update said the Factor asset acquisition included TPST-2003, a clinical-stage dual-targeting CD19/BCMA CAR-T with a strategic partner-funded China BLA filing planned for 2027, and the May update added a Head of Business Development focused on strategic partnerships, cross-border licensing, and corporate transactions [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].
Prob 35% • Move 25% • Priced-in 25%

Risks

Financing remains central because the March 2026 update described only $2 million upfront in the private placement, with additional proceeds dependent on warrant exercise [#SEC-8K-2026-03-30].
Large warrant stack and June 2026 stockholder approvals create ongoing dilution and exercise-overhang risk [#8-K-2026-06-23].
Low coverage and sparse external revision data make post-catalyst price discovery volatile and confidence low.
TPST-2003 still requires substantial U.S. development, manufacturing-transfer, regulatory, and clinical execution before the planned registrational path can support durable value [#SEC-8K-2026-05-14].
The China BLA and business-development path are longer-horizon options, not near-term operating proof, and depend on partner execution and transaction follow-through [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].

Peers

Symbol	Summary
HOWL	Loose same-sector micro-cap biotech comparator; useful mainly for framing binary clinical-readout trading and financing sensitivity rather than for operating metric parity.
BCDA	Another very small biotech peer with event-driven trading and capital-raising dependence; comparison is more about balance-sheet risk and catalyst volatility than direct program overlap.
ATOS	Micro-cap oncology/biotech peer that helps contextualize low-coverage sentiment swings and dilution risk, though program and indication match is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-25

AI Stock Memo: TPST - Tempest Therapeutics - RankAlpha